- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1750-1172
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Pricing and reimbursement of orphan drugs: the need for more transparency ; volume:6 ; number:1 ; day:17 ; month:6 ; year:2011 ; pages:1-8 ; date:12.2011
Orphanet journal of rare diseases ; 6, Heft 1 (17.6.2011), 1-8, 12.2011
- Creator
-
Simoens, Steven
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/1750-1172-6-42
- URN
-
urn:nbn:de:1111-2016050120203
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:52 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Simoens, Steven
- SpringerLink (Online service)
Other Objects (12)
Reimbursement of orphan drugs in Belgium: what (else) matters?
A systematic review of moral reasons on orphan drug reimbursement
Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs
Drug pricing and reimbursement decision making systems in Mongolia
The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe
Complex pricing and consumer-side transparency
Pricing and Reimbursement of Prescription Drugs in German Social Health Insurance
On the welfare analysis of external reference pricing and reimbursement policy
Approval, reimbursement and pricing of high-cost cancer medicines in Australia
Variables affecting pricing of orphan drugs: the Italian case
Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe
Reimbursement of orphan drugs in Belgium: what (else) matters?
A systematic review of moral reasons on orphan drug reimbursement
Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs
Drug pricing and reimbursement decision making systems in Mongolia
The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe
Complex pricing and consumer-side transparency
Pricing and Reimbursement of Prescription Drugs in German Social Health Insurance
On the welfare analysis of external reference pricing and reimbursement policy
Approval, reimbursement and pricing of high-cost cancer medicines in Australia
Variables affecting pricing of orphan drugs: the Italian case
Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe
Reimbursement of orphan drugs in Belgium: what (else) matters?
A systematic review of moral reasons on orphan drug reimbursement
Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs
Drug pricing and reimbursement decision making systems in Mongolia
The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe
Complex pricing and consumer-side transparency
Pricing and Reimbursement of Prescription Drugs in German Social Health Insurance
On the welfare analysis of external reference pricing and reimbursement policy
Approval, reimbursement and pricing of high-cost cancer medicines in Australia
Variables affecting pricing of orphan drugs: the Italian case